Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results

Day One Biopharmaceuticals (NASDAQ:DAWN) released its quarterly earnings data on Wednesday. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.58, Briefing.com reports. The firm had revenue of $93.76 million during the quarter, compared to analysts’ expectations of $15.05 million. During the same quarter in the previous year, the firm posted ($0.54) EPS.

Day One Biopharmaceuticals Stock Down 0.3 %

Shares of NASDAQ DAWN traded down $0.05 during trading on Friday, reaching $14.67. The company had a trading volume of 451,279 shares, compared to its average volume of 933,716. The business’s 50-day moving average is $14.18 and its 200 day moving average is $14.39. The stock has a market cap of $1.29 billion, a PE ratio of -14.29 and a beta of -1.51. Day One Biopharmaceuticals has a 12-month low of $10.90 and a 12-month high of $18.07.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the transaction, the general counsel now directly owns 26,928 shares of the company’s stock, valued at approximately $376,992. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Samuel C. Blackman sold 30,000 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the completion of the sale, the insider now directly owns 1,097,535 shares in the company, valued at approximately $15,606,947.70. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 3,202 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the transaction, the general counsel now directly owns 26,928 shares of the company’s stock, valued at approximately $376,992. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,748 shares of company stock worth $689,072 in the last quarter. Corporate insiders own 8.40% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on DAWN. Bank of America raised Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and raised their price target for the stock from $11.00 to $24.00 in a research note on Thursday, August 1st. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. JPMorgan Chase & Co. dropped their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday. Finally, Piper Sandler restated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.